Half-Year 2022 Financial and Clinical Trials Update

Ocrevus Global sales CHFbn CER growth +17% Regional sales 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 2,910m • US: Moving into earlier lines displacing orals; COVID-19 impact still felt • EU: Moving into earlier lines displacing orals; COVID-19 impact still felt CER-Constant Exchange Rates US CER growth +11% Europe +34% International +43% Roche 170

View entire presentation